CanBas Co., Ltd.

Privately held biopharmaceutical firm Polaris Group has reported positive Phase II results for its lead product, anticancer ADI-PEG 20, in malignant pleural mesothelioma (MPM), what looks to be its se

The Japanese venture CanBas is pressing ahead with plans for a Phase III clinical trial for its lead development project CBP501 in non-small cell lung cancer (NSCLC), despite mixed preliminary efficac

Takeda and the Japanese bioventure CanBas have terminated a global oncology R&D collaboration which was focusing on a novel therapy for lung cancer and mesothelioma. The two firms entered into a partn

A look at financing, M&A, and alliance activity July–September 2009 In this issue, we present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking—for the third quart